Drug Holds Promise for Patients With a Type of Leukemia
Dec. 3, 1999 (Tuscaloosa, Ala) -- In a study described as a "breakthrough" by a researcher at Oregon Health Sciences University, investigators will report Sunday that 31 of 31 patients with chronic myelogenous leukemia treated with an experimental pill went into total remission.
Chronic myelogenous leukemia (CML) is a form of leukemia, or cancer of the blood, that usually affects adults. It is treated with chemotherapy drugs and, when possible, bone marrow transplantation. The chemotherapy agents work to either kill the cancerous blood cells or keep them from multiplying. The average survival after diagnosis is four years.
The new drug compound is known as STI-571. "Early clinical trials are producing dramatic results with minimal side effects," Brian Druker, MD, one of the researchers, tells WebMD. "Unlike chemotherapy, which kills both normal and abnormal cells in an attempt to eradicate the cancer, the compound STI-571 targets an enzyme found only in CML."
Druker, an associate professor of medicine at Oregon Health Sciences University, points out that the enzyme is responsible for the overabundance of white blood cells characteristic of chronic myelogenous leukemia and is present in virtually all patients with CML.
The report, the results of collaboration with medical scientists at University of Texas MD Anderson Cancer Center, the Jonsson Cancer Center at UCLA, and Novartis Pharmaceuticals, is to be presented at the American Society of Hematology annual meeting in New Orleans.
"It's sort of like a light switch that is stuck on," Druker explains. "STI-571 targets that enzyme and inhibits its action."
The trial involved 31 CML patients who had failed to respond to standard treatment for their leukemia. Once the STI-571 dosage of 300 mg or greater was established, 31 of 31 patients had a complete normalization of their blood counts.
"Even more remarkable, in some cases the molecular cause of the disease seemed to disappear," Druker says.
The research may have implications for the treatment of other cancers.
"The potential significance of this research extends beyond leukemia," says Druker. "One of the major goals of cancer research has been to identify the differences between cancer cells and normal cells so that these differences can be targeted with more effective and less toxic treatments. That's exactly what we have been successfully doing in treating these patients."